Clinical

Articles

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma

The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate. 

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC

A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.

Looking at MCC Diagnoses Over Time Reveal Varying Effects Account for Incidence Rates

Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.

Study Finds Incidence Rates of cSCC Continue to Increase, Especially Among Females

A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.

Topical Immunosuppressants Drugs Don’t Increase Risk of Common Skin Cancers, Despite Warning Labels

Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.

PD-1 antibody Induces Clinical Activity in Patients with Locally Advanced Basal Cell Carcinoma

Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.

Personalized Cancer Vaccine Shows Long-Term Survival for Patients with High-Risk Melanoma

The FDA approved pembrolizumab for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma

Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.

Increases in Melanoma Risk in Patients Treated with Biologic Therapy Not Ruled Out

The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.

Skin Cancer | Topics